IKKε-Mediated Tumorigenesis Requires K63-Linked Polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 Ubiquitin Ligase Complex

Cell Reports

Volumn 3, Issue 3, 2013, Pages 724-733

  Zhou, Alicia Y ^a,b,c   Shen, Rhine R ^a,b,c   Kim, Eejung ^a,b,c   Lock, Ying J ^a,b,c   Xu, Ming ^d   Chen, Zhijian J ^d   Hahn, William C ^a,b,c  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE EPSILON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; INTERLEUKIN 1BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; UBIQUITIN PROTEIN LIGASE E3;

ARTICLE; CANCER CELL; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; INFLAMMATION; MACROPHAGE; MALIGNANT TRANSFORMATION; ONCOGENE; PRIORITY JOURNAL; PROTEIN BINDING; UBIQUITINATION;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; I-KAPPA B KINASE; INHIBITOR OF APOPTOSIS PROTEINS; INTERLEUKIN-1BETA; LYSINE; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS, EXPERIMENTAL; NF-KAPPA B; TNF RECEPTOR-ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84875810173     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2013.01.031     Document Type: Article

References (41)

1. Abbott D.W., Wilkins A., Asara J.M., Cantley L.C. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 2004, 14:2217-2227.
2. Aghajan M., Jonai N., Flick K., Fu F., Luo M., Cai X., Ouni I., Pierce N., Tang X., Lomenick B., et al. Chemical genetics screen for enhancers of rapamycin identifies a specific inhibitor of an SCF family E3 ubiquitin ligase. Nat. Biotechnol. 2010, 28:738-742.
3. Annunziata C.M., Davis R.E., Demchenko Y., Bellamy W., Gabrea A., Zhan F., Lenz G., Hanamura I., Wright G., Xiao W., et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007, 12:115-130.
4. Arkan M.C., Greten F.R. IKK- and NF-κB-mediated functions in carcinogenesis. Curr. Top. Microbiol. Immunol. 2011, 349:159-169.
5. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
6. Bassères D.S., Baldwin A.S. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830.
7. Bertrand M.J., Milutinovic S., Dickson K.M., Ho W.C., Boudreault A., Durkin J., Gillard J.W., Jaquith J.B., Morris S.J., Barker P.A. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol. Cell 2008, 30:689-700.
8. Bianchi K., Meier P. A tangled web of ubiquitin chains: breaking news in TNF-R1 signaling. Mol. Cell 2009, 36:736-742.
9. Boehm J.S., Zhao J.J., Yao J., Kim S.Y., Firestein R., Dunn I.F., Sjostrom S.K., Garraway L.A., Weremowicz S., Richardson A.L., et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell 2007, 129:1065-1079.
10. Brummelkamp T.R., Nijman S.M., Dirac A.M., Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-kappaB. Nature 2003, 424:797-801.
11. Chariot A., Leonardi A., Muller J., Bonif M., Brown K., Siebenlist U. Association of the adaptor TANK with the I kappa B kinase (IKK) regulator NEMO connects IKK complexes with IKK epsilon and TBK1 kinases. J. Biol. Chem. 2002, 277:37029-37036.
12. Chau T.L., Gioia R., Gatot J.S., Patrascu F., Carpentier I., Chapelle J.P., O'Neill L., Beyaert R., Piette J., Chariot A. Are the IKKs and IKK-related kinases TBK1 and IKK-epsilon similarly activated?. Trends Biochem. Sci. 2008, 33:171-180.
13. Fitzgerald K.A., McWhirter S.M., Faia K.L., Rowe D.C., Latz E., Golenbock D.T., Coyle A.J., Liao S.M., Maniatis T. IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. Nat. Immunol. 2003, 4:491-496.
14. Guo J., Kim D., Gao J., Kurtyka C., Chen H., Yu C., Wu D., Mittal A., Beg A.A., Chellappan S.P., et al. IKBKE is induced by STAT3 and tobacco carcinogen and determines chemosensitivity in non-small cell lung cancer. Oncogene 2013, 32:151-159.
15. Guo J.P., Coppola D., Cheng J.Q. IKBKE protein activates Akt independent of phosphatidylinositol 3-kinase/PDK1/mTORC2 and the pleckstrin homology domain to sustain malignant transformation. J. Biol. Chem. 2011, 286:37389-37398.
16. Hayden M.S., Ghosh S. Signaling to NF-kappaB. Genes Dev. 2004, 18:2195-2224.
17. Hutti J.E., Shen R.R., Abbott D.W., Zhou A.Y., Sprott K.M., Asara J.M., Hahn W.C., Cantley L.C. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol. Cell 2009, 34:461-472.
18. Israël A. The IKK complex, a central regulator of NF-kappaB activation. Cold Spring Harb. Perspect. Biol. 2010, 2:a000158.
19. Iwai K., Tokunaga F. Linear polyubiquitination: a new regulator of NF-kappaB activation. EMBO Rep. 2009, 10:706-713.
20. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
21. Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu. Rev. Immunol. 2000, 18:621-663.
22. Kovalenko A., Chable-Bessia C., Cantarella G., Israël A., Wallach D., Courtois G. The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination. Nature 2003, 424:801-805.
23. Lydeard J.R., Harper J.W. Inhibitors for E3 ubiquitin ligases. Nat. Biotechnol. 2010, 28:682-684.
24. Ng S.L., Friedman B.A., Schmid S., Gertz J., Myers R.M., Tenoever B.R., Maniatis T. IκB kinase epsilon (IKK(epsilon)) regulates the balance between type I and type II interferon responses. Proc. Natl. Acad. Sci. USA 2011, 108:21170-21175.
25. Perkins N.D. Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat. Rev. Mol. Cell Biol. 2007, 8:49-62.
26. Peters R.T., Liao S.M., Maniatis T. IKKepsilon is part of a novel PMA-inducible IkappaB kinase complex. Mol. Cell 2000, 5:513-522.
27. Pickart C.M., Eddins M.J. Ubiquitin: structures, functions, mechanisms. Biochim. Biophys. Acta 2004, 1695:55-72.
28. Pomerantz J.L., Baltimore D. NF-kappaB activation by a signaling complex containing TRAF2, TANK and TBK1, a novel IKK-related kinase. EMBO J. 1999, 18:6694-6704.
29. Shih V.F., Tsui R., Caldwell A., Hoffmann A. A single NFκB system for both canonical and non-canonical signaling. Cell Res. 2011, 21:86-102.
30. Shimada T., Kawai T., Takeda K., Matsumoto M., Inoue J., Tatsumi Y., Kanamaru A., Akira S. IKK-i, a novel lipopolysaccharide-inducible kinase that is related to IkappaB kinases. Int. Immunol. 1999, 11:1357-1362.
31. Skaug B., Jiang X., Chen Z.J. The role of ubiquitin in NF-kappaB regulatory pathways. Annu. Rev. Biochem. 2009, 78:769-796.
32. Tang E.D., Wang C.Y., Xiong Y., Guan K.L. A role for NF-kappaB essential modifier/IkappaB kinase-gamma (NEMO/IKKgamma) ubiquitination in the activation of the IkappaB kinase complex by tumor necrosis factor-alpha. J. Biol. Chem. 2003, 278:37297-37305.
33. Tenoever B.R., Ng S.L., Chua M.A., McWhirter S.M., García-Sastre A., Maniatis T. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science 2007, 315:1274-1278.
34. Trompouki E., Hatzivassiliou E., Tsichritzis T., Farmer H., Ashworth A., Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-kappaB activation by TNFR family members. Nature 2003, 424:793-796.
35. Tu D., Zhu Z., Zhou A.Y., Yun C., Lee K.-E., Toms A.V., Li Y., Dunn G.P., Chan E., Thai T., et al. Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013, 3. Published online February 28, 2013. 10.1016/j.celrep.2013.01.033.
36. Vince J.E., Pantaki D., Feltham R., Mace P.D., Cordier S.M., Schmukle A.C., Davidson A.J., Callus B.A., Wong W.W., Gentle I.E., et al. TRAF2 must bind to cellular inhibitors of apoptosis for tumor necrosis factor (tnf) to efficiently activate nf-kappab and to prevent tnf-induced apoptosis. J. Biol. Chem. 2009, 284:35906-35915.
37. Xie X., Zhang D., Zhao B., Lu M.K., You M., Condorelli G., Wang C.Y., Guan K.L. IkappaB kinase epsilon and TANK-binding kinase 1 activate AKT by direct phosphorylation. Proc. Natl. Acad. Sci. USA 2011, 108:6474-6479.
38. Xu M., Skaug B., Zeng W., Chen Z.J. A ubiquitin replacement strategy in human cells reveals distinct mechanisms of IKK activation by TNFalpha and IL-1beta. Mol. Cell 2009, 36:302-314.
39. Yin Q., Lamothe B., Darnay B.G., Wu H. Structural basis for the lack of E2 interaction in the RING domain of TRAF2. Biochemistry 2009, 48:10558-10567.
40. Zarnegar B.J., Wang Y., Mahoney D.J., Dempsey P.W., Cheung H.H., He J., Shiba T., Yang X., Yeh W.C., Mak T.W., et al. Noncanonical NF-kappaB activation requires coordinated assembly of a regulatory complex of the adaptors cIAP1, cIAP2, TRAF2 and TRAF3 and the kinase NIK. Nat. Immunol. 2008, 9:1371-1378.
41. Zhou H., Wertz I., O'Rourke K., Ultsch M., Seshagiri S., Eby M., Xiao W., Dixit V.M. Bcl10 activates the NF-kappaB pathway through ubiquitination of NEMO. Nature 2004, 427:167-171.